search results
Image 134 of 229
Less

ET-D5_026.jpg

Add to Lightbox Download

Preparation of ET-D5.

ET-D5 is an anti-cancer molecule that can kill cancer tumors without damaging nearby organs.
ET-D5 is developed by the start-up Ecrins -Therapeutics, founded in 2010.
Oral chemotherapy.
Aurélie Juhem, scientist and research director at Ecrins Therapeutics, is working on this molecule cancer for seven long years in partnership with the Institut Curie.
Many promising tests have already been carried out on mouses.
To move to the next stage, clinical trials in humans, the young start-up must raise € 500,000.
The Financement of this research will be done through a platform of "crowdfunding".
When this amount will be found, the first human trials could begin on patients of cancer center Léon Bérard in Lyon.

Copyright
Bruno Vigneron
Image Size
5000x3337 / 11.3MB
Keywords
Contained in galleries
ET-D5
Preparation of ET-D5.<br /> <br /> ET-D5 is an anti-cancer molecule that can kill cancer tumors without damaging nearby organs.<br /> ET-D5 is developed by the start-up Ecrins -Therapeutics, founded in 2010.<br /> Oral chemotherapy.<br /> Aurélie Juhem, scientist and research director at Ecrins Therapeutics, is working on this molecule cancer for seven long years in partnership with the Institut Curie.<br /> Many promising tests have already been carried out on mouses.<br /> To move to the next stage, clinical trials in humans, the young start-up must raise € 500,000.<br /> The Financement of this research will be done through a platform of "crowdfunding".<br /> When this amount will be found, the first human trials could begin on patients of cancer center Léon Bérard in Lyon.